How to Measure Biological Age: All Methods Compared
Epigenetic, blood-based, proteomic, functional and imaging measures all estimate biological age from different evidence. A structured comparison of what each one reads and costs.
The Short Answer
There are five practical families of biological age measurement: epigenetic clocks built on DNA methylation, composite measures built from routine blood biomarkers, proteomic and metabolomic measures built from plasma molecules, functional measures built from physical and cognitive performance, and imaging-derived measures built from retinal photographs or brain scans. They differ in cost by two orders of magnitude, in what tissue they read, and in whether they estimate accumulated age or the current rate of aging. No single method is authoritative, and combining a molecular measure with a functional one produces a more reliable picture than either alone.
Epigenetic Clocks
What they read. Methylation status at specific cytosine-guanine sites across the genome, usually from blood, sometimes from saliva or buccal cells.
How they work. A machine learning model is trained on methylation data from thousands of people, selecting the sites that best predict a target. First-generation clocks predict chronological age. Second-generation clocks predict mortality or clinical composites. Third-generation measures predict the rate of change from longitudinal cohorts.
Strengths. The most extensively validated molecular approach, with a large literature linking acceleration to outcomes. Requires only a blood spot or saliva sample. Reads a mechanism with genuine mechanistic standing, since epigenetic alteration is itself one of the recognised hallmarks of aging.
Weaknesses. Test-retest variability can exceed a year on some platforms. Results depend on which cells are in the sample, so shifts in white cell composition register as age changes. Different clocks disagree on the same sample. Consumer services often do not disclose which model they use or report any uncertainty.
Cost and access. Consumer testing typically ranges from moderate to expensive, with turnaround of weeks. Research-grade arrays are more expensive again.
Blood Biomarker Composites
What they read. Routine clinical chemistry: albumin, creatinine, glucose, C-reactive protein, alkaline phosphatase, white cell count and distribution, red cell indices and similar.
How they work. A statistical model, historically the Klemera-Doubal method or a mortality-trained regression, combines the markers into a single value expressed in years. Phenotypic age measures of this type are the direct ancestors of the second-generation epigenetic clocks, which were in several cases trained to predict these composites.
Strengths. Inexpensive, since it uses tests already performed in routine care. Interpretable, because the inputs are individually meaningful and individually actionable. Well validated against mortality in large cohorts. Responsive over months, which suits intervention tracking.
Weaknesses. Sensitive to acute states, since inflammation, hydration and recent illness all move inputs. Reflects current physiological state more than accumulated damage, which is a strength for tracking and a weakness for estimating cumulative aging.
Cost and access. The cheapest credible option. A standard panel plus a published formula, and several free calculators implement the published models.
Proteomic, Metabolomic and Glycan Measures
What they read. Hundreds to thousands of plasma proteins, or metabolite profiles, or the glycosylation patterns of circulating antibodies.
How they work. Large-scale profiling plus a model trained against age or outcome. The most interesting recent development is organ-specific estimation: because many plasma proteins originate predominantly in one tissue, a single blood draw can yield separate age estimates for heart, brain, liver, kidney and immune system, and those estimates diverge substantially within the same person.
Strengths. Organ-level resolution that no single-value measure can provide. Proteins are functionally closer to physiology than methylation marks. Rapidly improving.
Weaknesses. Expensive. Platform-dependent, with limited standardisation between providers. Less longitudinal outcome validation than epigenetic measures. Interpretation frameworks for consumers are immature.
Cost and access. Currently the most expensive family, largely research-based, with early consumer availability.
Functional and Performance Measures
What they read. Grip strength, gait speed, chair-stand repetitions, balance time, forced expiratory volume, visual and auditory acuity, reaction time and cognitive performance.
How they work. Individual measures are compared against age and sex norms, or combined into a composite. Frailty indices and physiological age batteries have decades of use in geriatric research.
Strengths. Free or nearly free. Immediately meaningful, since these measures are what aging feels like rather than a proxy for it. Strongly predictive: grip strength and gait speed independently predict mortality in large cohorts with effect sizes comparable to molecular measures. Repeatable weekly without cost.
Weaknesses. Influenced by training status, so a strength-trained person scores well on grip regardless of underlying biology. Less sensitive in younger adults, since functional decline is not yet apparent. Requires consistent technique to be comparable over time.
Cost and access. A grip dynamometer, a chair, a stopwatch. This is the most underused family of measures by a wide margin.
Imaging-Derived Measures
What they read. Retinal photographs, brain magnetic resonance images, coronary calcium scores, or dual-energy X-ray absorptiometry body composition.
How they work. Deep learning models trained on large imaging datasets estimate age from image features. Retinal age models have shown that the retina, being neural and vascular tissue that can be photographed non-invasively, carries substantial age information, and retinal age gap has been associated with mortality in large cohorts. Brain age models estimate structural aging in the central nervous system specifically.
Strengths. Organ-specific and directly structural. Retinal imaging is cheap and non-invasive. Coronary calcium is a well-established prognostic measure in its own right.
Weaknesses. Availability is uneven. Model outputs are rarely accessible outside research settings. Brain imaging is expensive and not repeatable often.
Side-by-Side Comparison
| Method | Reads | Estimates | Relative cost | Best used for |
|---|---|---|---|---|
| Epigenetic clock (2nd gen) | DNA methylation in blood or saliva | Accumulated age, outcome-weighted | High | Baseline and long-interval tracking |
| Pace-of-aging measure | DNA methylation, longitudinally trained | Current rate of aging | High | Evaluating an intervention |
| Blood biomarker composite | Routine clinical chemistry | Current physiological state | Low | Frequent tracking, actionable inputs |
| Proteomic / organ-specific | Plasma proteins | Organ-level age | Very high | Locating the limiting system |
| Functional battery | Strength, gait, balance, lung function | Functional age | Very low | Continuous, honest feedback |
| Retinal or brain imaging | Tissue structure | Organ-specific structural age | Variable | Specialist context |
A Practical Measurement Strategy
Given cost, variability and the absence of any single authoritative method, a sensible strategy layers the families rather than choosing between them.
Foundation, no cost. Functional measures every one to three months: grip strength, chair-stand time, resting heart rate, a paced walk or run, waist circumference. These respond to real change and cannot be gamed by measurement noise.
Core, low cost. A standard blood panel twice yearly, entered into a published phenotypic age formula. This gives an actionable composite plus the individual markers that indicate what to work on.
Anchor, higher cost. One epigenetic measure at baseline and again at twelve to twenty-four months, with the same provider and preferably a second-generation or pace-of-aging model rather than a first-generation clock.
Optional. Proteomic or organ-specific testing where the layered approach has flagged something specific and the additional resolution would change a decision.
The common error is inverting this: paying for the most expensive measure, repeating it too often, and neglecting the free measures that carry comparable predictive weight.
The AEONNN Perspective
AEONNN Age is a composite by design rather than a wrapper around one laboratory test, and the comparison above is the reason. Each measurement family has a characteristic blind spot: epigenetic clocks carry assay noise and cell-composition sensitivity, blood composites reflect current state more than accumulation, functional measures are confounded by training status, proteomic measures lack longitudinal validation. A composite that draws on what is available, and that states its confidence according to what is available, is more honest than a single number presented with borrowed authority.
This is where Discovered and Synched Modes differ concretely. Discovered Mode builds the composite from self-reported context, routines and constraints, and says plainly that its confidence is lower. Synched Mode incorporates connected wearable and laboratory data, and the composite tightens accordingly. Same architecture, different information quality, different stated confidence.
It is also worth noting what AEONNN Age is not: it is not an epigenetic clock result, and it is not a diagnosis. It is a composite in age-like format whose job is to make a trajectory legible across ten Pillars, and whose value comes from being recomputed as context changes rather than from any single reading.
Pillar Matrix mapping
Database Matrix layers
- Evidence Layer (PubMed, Cochrane, ClinicalTrials.gov)
- Meta / Consensus Layer (JAMA, BMJ, specialty society positions)
- Population Layer (UK Biobank, NHANES)
- Quality / Formulation Layer (ConsumerLab, Labdoor)
- Innovation Layer (bioRxiv preprints, patent filings)
Frequently Asked
What is the most accurate biological age test?
No single test is authoritative. Second-generation epigenetic clocks have the most outcome validation, blood biomarker composites are the most interpretable and repeatable, and functional measures such as grip strength and gait speed predict mortality with effect sizes comparable to molecular measures at almost no cost.
Are at-home biological age tests worth it?
They can be, with caveats. Prefer providers that disclose which model they use, report uncertainty, and use a second-generation or pace-of-aging model. Use the same provider for repeat testing, and leave at least twelve months between measurements.
Can I calculate biological age from a normal blood test?
Yes. Published phenotypic age formulas use routine markers such as albumin, creatinine, glucose, C-reactive protein, alkaline phosphatase and white cell indices. This is the cheapest credible approach and the inputs are individually actionable.
How do organ-specific age measures work?
Many plasma proteins originate predominantly in one tissue, so a proteomic panel can produce separate estimates for heart, brain, liver, kidney and immune system from a single blood draw. Those estimates commonly diverge within the same person.
Is grip strength really a biological age measure?
Grip strength and gait speed are among the strongest independent predictors of mortality and functional decline in large cohorts. They are confounded by training status, which is a limitation, but they are free, repeatable and closer to lived function than any molecular proxy.
How often should each type of test be repeated?
Functional measures monthly to quarterly. Blood panels twice yearly. Epigenetic measures every twelve to twenty-four months. Repeating an epigenetic test every few months mostly measures assay variability.
Do I need an epigenetic test at all?
Not necessarily. A layered approach using functional measures and a blood composite delivers most of the actionable value at a fraction of the cost. An epigenetic measure is a useful long-interval anchor rather than the centrepiece.
Evidence and review
Any dosage ranges cited here reflect the ranges used in published human trials, not personal recommendations. Evidence in this field moves, so this article is reviewed quarterly and carries its last-updated date above. Nothing here is intended as medical advice, and supplementation should be discussed with a qualified clinician, particularly alongside prescribed medication or an existing condition.